The objective of this study is to evaluate the safety and efficacy of priming vaccinations, and subsequent boosting vaccinations with GVAX® Vaccine for Prostate Cancer. Clinical observations and laboratory measurements will be monitored to evaluate safety and toxicity. Additionally, the antitumor effects of GVAX® Vaccine for Prostate Cancer on serum PSA levels, will be evaluated and antitumor responses will be quantitated.

Inclusion Criteria:

• Diagnosis of adenocarcinoma prostate cancer that has recurred after surgery by PSA
• No evidence of measurable metastatic disease
• An ECOG performance status of 0 or 1

Exclusion Criteria:

• Transitional cell, small cell or squamous cell prostate carcinomas
• Any previous radiation therapy, prior anti-androgens or prior investigational therapy
• Previous hormonal therapy of any type for prostate cancer
• Previous biological therapy for cancer